Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein | Zendy

Paul M. Ridker | Zendy; Eleanor Danielson | Zendy; Francisco Antônio Helfenstein Fonseca | Zendy; Jacques Genest | Zendy; Antonio M. Gotto | Zendy; John J.P. Kastelein | Zendy; Wolfgang Köenig | Zendy; Peter Libby | Zendy; Alberto J. Lorenzatti | Zendy; Jean MacFadyen | Zendy; Børge G. Nordestgaard | Zendy; James Shepherd | Zendy; James T. Willerson | Zendy; Robert J. Glynn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Author(s) -

Paul M. Ridker,

Eleanor Danielson,

Francisco Antônio Helfenstein Fonseca,

Jacques Genest,

Antonio M. Gotto,

John J.P. Kastelein,

Wolfgang Köenig,

Peter Libby,

Alberto J. Lorenzatti,

Jean MacFadyen,

Børge G. Nordestgaard,

James Shepherd,

James T. Willerson,

Robert J. Glynn

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0807646

Subject(s) - rosuvastatin , medicine , hazard ratio , c reactive protein , rosuvastatin calcium , myocardial infarction , confidence interval , statin , placebo , unstable angina , cardiology , endocrinology , gastroenterology , inflammation , pathology , alternative medicine

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research